AbbVie reported better-than-expected fourth-quarter earnings. Strong demand for the company's Skyrizi and Rinvoq autoimmune therapeutics has helped offset the decline in Humira sales since losing ...

AbbVie's Rinvoq and Skyrizi could eventually surpass Humira's peak sales. The dividend is well-funded, though an expensive acquisition spree may lead to slower growth. The stock's solid growth ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...

Ten months after Pfizer scored approval in Europe for Emblaveo (aztreonam and avibactam) to treat complicated intra-abdominal infections (cIAIs), AbbVie has done the same in the U.S., winning an ...

AbbVie and Neomorph are forming a partnership and option-to-license agreement to develop molecular glue degraders, aiming to introduce a new class of treatments across oncology and immunology.

Shares of AbbVie Inc. (NYSE:ABBV) surged after the company reported strong Q4 2024 results and provided in-line revenue guidance and better-than-expected EPS guidance for 2025. I am very pleased ...

AbbVie (NYSE:ABBV) will report Q4 2024 results next week and provide guidance for 2025. The company is handling the erosion of Humira quite well, but the trajectory of the decline in Humira's net ...

AbbVie has been named a Top Socially Responsible Dividend Stock by Dividend Channel, signifying a stock with above-average ''DividendRank'' statistics including a strong 3.9% yield, as well as ...

AbbVie forecasts 7% growth in 2025 and 10-11% in 2026-2027 for its immunology segment. Goldman Sachs raises AbbVie’s price target to $208, citing Skyrizi and Rinvoq as key growth drivers. Get ...

AbbVie (NYSE:ABBV) continues to navigate the challenges of Humira's loss of exclusivity while leveraging its diverse portfolio and robust pipeline to drive future growth. With a gross profit ...

Shares of AbbVie (NYSE: ABBV) were jumping 7.1% higher as of 11:10 a.m. ET on Friday after rising as much as 9.2% earlier in the day. The nice gain stemmed from the big drugmaker's 2024 fourth ...